Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

DUBLIN, October 28, 2011 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.

Financial Highlights Q3 2011(1) Product sales $1,018 million +28% Total revenues $1,086 million +24% Non GAAP operating income $341 million +15% US GAAP operating income $255 million +64% Non GAAP diluted earnings per ADS $1.28 +10% US GAAP diluted earnings per ADS $1.02 +96% Non GAAP cash generation $296 million +9% Non GAAP free cash flow $138 million +56% US GAAP net cash provided by operating activities $179 million +26%

(1)    Percentages compare to equivalent period in 2010.

The Non GAAP financial measures included within this release are explained on page 24, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 23.

Angus Russell, Chief Executive Officer, commented:

"Shire has delivered another strong set of quarterly results. Total product sales were up 28% to $1,018 million, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter. We're on track to deliver significant 2011 earnings growth.

Sales of our rare disease treatments were very strong: with VPRIV up 31% and REPLAGAL up 40% versus the same quarter in 2010. FIRAZYR, our self-administered treatment for acute attacks of Hereditary Angioedema, was approved by the FDA in August and launched just a few weeks ago; initial demand from patients has been positive. This week we have also initiated a rolling Biologics License Application for REPLAGAL in the US, designated Fast Track by the FDA.

The US ADHD market continues to grow and with a strong 'back to school' season, our portfolio of treatments has gained sha
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 21, 2015 Research and Markets ( ... "Biomedical Refrigerators and Freezers Market - Global ... 2014 - 2022" report to their offering. ... freezers market has been segmented based on applications: ... and others. The others segment includes applications of ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/27/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Thursday, July 30, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
Breaking Biology Technology:Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... The Board of,Directors of Shire Limited (LSE: SHP)(NASDAQ: ... today that Graham Hetherington will,join the Company as ... July 2008., Graham Hetherington has a broad ... recently held positions as the Chief Financial Officer ...
... (Amex: ETC ) ("ETC" or the "Company") ... (7) BARA-MED(R) XD,Monoplace Hyperbaric Chambers to Med One ... Haelen Hyperbarics., ETC is delighted to work ... Hyperbaric Oxygen Therapy (HBOT) clinics. Haelen,Hyperbarics also provides ...
... reduction technology to, further reduce risk of variant Creutzfeldt-Jakob ... ... - Octapharma sponsoring lunchtime Symposium at meeting to discuss prion ... quality., MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10,/PRNewswire-FirstCall/ - ...
Cached Biology Technology:Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire 2Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire 3Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 2Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... to feed exclusively on blood, including human blood, recognize their ... published today in the open access journal BMC Biology, vampire ... breathing sounds much better than human participants could. Vampire bats ... authors of the study propose that the bats use breathing ...
... cellular process of transcription, in which the enzyme RNA ... DNA, depends upon previously underappreciated sections of both the ... done with the bacterium E. coli and published today ... of bacteriologists from the University of Wisconsin-Madison. , ...
... mountain range found surviving members of a species of ... wiping out amphibian populations in Central and South America. ... population of the painted frog (Atelopus ebenoides marinkellei) indicates ... other species also might avoid elimination from the epidemic ...
Cached Biology News:Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 3Colombian frog believed extinct found alive 2
Verotoxin IIbeta (457)...
... The Universal Vacuum System UVS400 is a ... The UVS400 combines a refrigerated vapor trap ... a single integrated unit. The easy-to-use, wide-mouth ... solvent into single jar for easy disposal. ...
Lysozyme C (W-20)...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: